Review Article

Progress and Understandings in the Pharmacological Repositioning Scenario

Lara Bianca Soares Brandão
Federal University of Campina Grande, Brazil
Dicla Aline Semedo da Veiga
Federal University of Campina Grande, Brazil
Hélida Maravilha Dantas e Sousa Almeida
Federal University of Rio Grande do Norte, Brazil
* Corresponding author
Igor de Sousa Oliveira
Federal University of Campina Grande, Brazil
Sávio Benvido Ferreira
Federal University of Campina Grande, Brazil
DOI icon 10.24018/ejmed.2023.5.1.1660

Read Counter
304

Downloads
208

Citations

Share

Article Sidebar

Submitted 2023-01-14
Published 2023-02-18

Read counter = 304 times

Table of Contents

Article Main Content

In order to present an overview of pharmacological repositioning in terms of clinical applicability, a narrative review was applied, based on the PCC strategy. The search was carried out in February 2022, highlighting the concepts on the subject, not requiring the opinion of a committee for its development. Numerous drugs were randomly repositioned. It is noteworthy that during clinical trials, unexpected side effects made its reuse possible. The antiplatelet effect of aspirin is already elucidated, however, research reveals potential in oncology. Therefore, there is a need to explore the biochemistry and the interaction with organic and pathological targets, visualizing the applicability of known drugs in solving urgent problems.

Keywords: Delivery of healthcare drug development drug repositioning

References

  1. Scherman D, Fetro C. Drug repositioning for rare diseases: Knowledge-based success stories. Therapie. 2020; 75(2): 161-167.
    DOI  |   Google Scholar
  2. Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; (3): 673-683.
    DOI  |   Google Scholar
  3. Armando RG, Mengual, DL, Gomez, DE. New drugs are not enough‑drug repositioning in oncology: An update. Int J Oncol. 2020; 56(3): 651-684.
    DOI  |   Google Scholar
  4. Scannell JW, Blanckley A, Boldon H, Brian W. Diagnosing the decline in pharmaceutical R&D efficiency. Nat Rev Drug Discov. 2012; 11(3): 191-200.
    DOI  |   Google Scholar
  5. Rodriguez-Esteban R. A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease. PLoS Comput Biol. 2016; 12(4).
    DOI  |   Google Scholar
  6. Jourdan JP, Bureau R, Rochais C, Dallemagne P. Drug repositioning: a brief overview, Journal of Pharmacy and Pharmacology. 2020; 72(9): 1145-1151.
    DOI  |   Google Scholar
  7. Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019; 18(1):41-58.
    DOI  |   Google Scholar
  8. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting systematic scoping reviews. Int J Evid Based Healthc. 2015; 13(3): 141-146.
    DOI  |   Google Scholar
  9. Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E. From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2?, J. Travel Medicine. 2021; 28(2).
    DOI  |   Google Scholar
  10. Nosengo N. Can you teach old drugs new tricks? Nature. 2016; 534: 314-316.
    DOI  |   Google Scholar
  11. Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL. How to Improve R&D Productivity: the Pharmaceutical Industry’s Grand Challenge. Nature Reviews: Drug Discovery. 2010; 9: 203-214.
    DOI  |   Google Scholar